Overview

* Acumen Q2 net loss widens to $41.0 mln, driven by increased R&D expenses

* Cash reserves of $166.2 mln expected to support operations into early 2027

Outlook

* Cash reserves expected to support operations into early 2027

Result Drivers

* SCREENING INNOVATIONS - Co implemented a two-step screening process in ALTITUDE-AD phase 2 clinical trial, reducing costs by 40% across U.S. and Canadian sites and improving enrollment rates

* R&D EXPENSES - Increased R&D expenses driven by manufacturing and materials costs for ALTITUDE-AD trial

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net -$40.95

Income mln

Q2 Basic -$0.68

EPS

Q2 -$41.75

Income mln

From

Operatio

ns

Q2 $41.75

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Acumen Pharmaceuticals Inc ( ABOS ) is $10.00, about 85.8% above its August 11 closing price of $1.42

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)